Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients (2-<18 years old) with iron overload A deferazirox továbbfejlesztett gyógyszerformájának (granulátum) hatásosságát és biztonságosságát, valamint a kezeléssel való együttműködést értékelő vizsgálat vastúlterhelésben szenvedő (2 ‒ < 18 éves) gyermekeknél
1. To evaluate both formulations on patient compliance, using stick pack/tablet count in ICT naive patients 2. To evaluate the change from baseline in serum ferritin at 48 weeks of treatment for both...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane
to evaluate safety of everolimus (RAD001) in postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer after recurrence or progression following NSAIs treatment
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A clinical study of oral ceritinib in patients with ALK-Positive Non-Small Cell Lung Cancer metastatic to the brain and/or to leptomeninges
The primary objective is to evaluate the antitumor activity of Ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or to leptomeninges.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
Étude CPIM447X2104C : étude de phase 1, en escalade de dose, évaluant la tolérance de l’association du ruxolitinib, un inhibiteur de JAK1/2,avec le PIM447, un inhibiteur de PIM ou le LEE011, un inhibiteur de CDK4/6, ou les deux, chez des patients ayant une myélofibrose. [essai clos aux inclusions]
La myélofibrose est un cancer rare de la moelle osseuse caractérisé par un développement et un fonctionnement anormaux des cellules sanguines produites dans la moelle osseuse, qui donne lieu à la form...
Country
France
organs
Sang Hématologie - Autres
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study of GSK1120212 compared with chemotherapy in patients with BRAF mutation positive advanced or metastatic melanoma
The primary objective for this study is to establish the superiority of GSK1120212 over chemotherapy with respect to progression-free survival for subjects with advanced/metastatic BRAF V600E mutation...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of safety and efficacy of INC280 alone, and in combination with erlotinib, compared to chemotherapy, in advanced/metastatic non-small cell lung cancer patients with EGFR mutation and cMET amplification
Phase Ib: To determine MTD and/or RP2D of INC280 in combination with erlotinib Phase II: To compare the antitumor activity of INC280 alone, and INC280 in combination with erlotinib, vs platinum with ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of efficacy and safety of INC424 in regularly transfused patients with thalassemia
To assess the effect of INC424 on transfusion requirement
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A Study to Test Trametinib and dabrafenib in Children and Adolescents Subjects with Cancer
To determine the safe and tolerable trametinib dose(s) for chronic continuous daily dosing in pediatric subjects (infants, children, and adolescents) that achieves similar exposures (trough concentrat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations
To evaluate the effect of ruxolitinib in delaying progression of MF from early disease to more advanced disease stages.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients with type 2 diabetes fasting during Ramadan
To evaluate in Muslim patients with T2DM who plan to fast during the Ramadan fasting period: The proportion of patients with at least one HE (Hypoglycaemic event) is lower in the vildagliptin pl...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next